Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.

Ghadyalpatil, N.; Prabhash, K.; Menon, Hari; Nair, Raunak; Banavali, Shripad; Noronha, Vanita; Wabale, Vaishali; Singh, Ragini; Goyal, Gaurav; Ostwal, Vikas

doi:10.1200/jco.2010.28.15_suppl.6594

Cited by 4 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors of that paper concluded that host tyrosine kinases may be implicated in entry and intracellular survival of mycobacteria and discussed that imatinib may have therapeutic efficacy against M. tuberculosis . These observations are consistent with the analysis by Ghadyalpatil et al [9] which showed no evidence of reactivation of tuberculosis under IM. Thus, it remains unclear why a small subset of patients, including ours, receiving IM treatment develops tuberculous lymphadenitis.…”

Section: Discussionsupporting

confidence: 93%

“…To date, a total of 9 patients have been reported to have developed tuberculosis under or after IM treatmen; most of them had CML (n = 8) [7, 8, 9, 10] and only 1 patient had GIST [6]. The clinicopathological features of these patients are summarized in table 1.…”

Section: Discussionmentioning

confidence: 99%

“…Ghadyalpatil et al [9] analyzed data of 1,100 CML patients treated with IM and followed up for possible reactivation of tuberculosis for a period of 6–156 months (mean 49). None of the 21 patients with a confirmed history of tuberculosis showed evidence of reactivation.…”

Section: Discussionmentioning

confidence: 99%

“…The review by Ghadyalpatil et al [9] showed that previous history of tuberculosis does not represent a risk for reactivation under IM treatment as none of the patients with a positive history for tuberculosis developed reactivation. On the contrary, Daniels et al [8] reported similar findings in 3 patients with probable previous contact with tuberculosis and considered a reactivation as the most likely event in their cases.…”

Section: Discussionmentioning

confidence: 99%

“…Mycobacterial infection is not associated with IM treatment, since only 9 patients have been reported who developed tuberculosis during or after IM treatment for chronic myelogenous leukemia (CML, n = 8) and GIST (n = 1) [6, 7, 8, 9, 10]. In this report, we present our experience with 2 patients who developed lymphadenopathy under IM treatment for metastatic GIST.…”

Section: Introductionmentioning

confidence: 98%

See 4 more Smart Citations

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Agaimy¹,

Brueckl²,

Schmidt

et al. 2013

Case Rep Oncol

View full text Add to dashboard Cite

Background: Imatinib mesylate (IM) is the standard treatment for BCR-ABL-positive chronic myelogenous leukemia (CML) and is the first-line adjuvant and palliative treatment for metastatic and inoperable gastrointestinal stromal tumor (GIST). IM is not known to be associated with an increased risk for development of granulomatous diseases. Methods: We describe our experience with 2 patients (42 and 62 years of age) who developed granulomatous disease during IM treatment for metastatic GIST. Results: Mean duration of IM treatment was 12 (range 8-16) months. Enlarged lymph nodes with increased metabolism on FDG-PET-CT examination were detected and resected. Affected sites were supraclavicular (1) and subcarinal/mediastinal (1) lymph nodes. Histological examination revealed caseating and non-caseating granulomas suggestive of tuberculosis and sarcoidosis, respectively. Mycobacterium tuberculosis was detected by PCR in lymph nodes of 1 patient who was then successfully treated by anti-tuberculous agents. The other patient had negative sputum test for acid-fast bacilli and PCR-DNA-analysis was negative for M. tuberculosis and other mycobacteria. He received no anti-tuberculous therapy and had no evidence of progressive lymphadenopathy or new lung lesions during follow-up. Conclusion: Our observations underline the necessity to obtain biopsy material from enlarged or metabolically active lymph nodes developing during IM treatment for timely diagnosis and appropriate treatment of these rare complications. Follow-up without treatment is safe for patients without detectable microorganisms by sputum examination and PCR.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 3 more Smart Citations

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Agaimy¹,

Brueckl²,

Schmidt

et al. 2013

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

Risk and impact of tuberculosis in patients with chronic myeloid leukemia: A nationwide population‐based study in Taiwan

Liu

Hong

Teng

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

The relationship between chronic myeloid leukemia (CML) and tuberculosis (TB) has not been determined. We conducted a national survey including 1,082 CML patients identified from the Taiwan National Health Insurance database covering a period between 1998 and 2011; the matched non-exposed cohort included 10,820 subjects without CML that were matched for age, sex and comorbidities. The impact of TB was measured by the overall mortality, and the risk factors were identified by a multivariate Cox proportional hazards model. We found the risk of TB was higher in the CML cohort, with an adjusted hazard ratio (aHR) of 3.76 (p 5 0.001) for both pulmonary (aHR 3.23, p < 0.001) and extrapulmonary (aHR 9.77, p 5 0.001) TB. Specific risk factors were: aged 60 (aHR 3.24, p 5 0.022), being male (aHR 13.49, p 5 0.012), receiving stem cell transplantation (aHR 10.50, p 5 0.001) and interferon-a therapy (aHR 3.34, p 5 0.011). CML patients with TB had a higher mortality rate than those without (aHR 2.04, p 5 0.043). We conclude that the incidence of TB is significantly higher in CML patients of male sex, aged 60, having received either stem cell transplantation or interferon-a treatment. Careful screening strategies for TB should be considered for CML patients with high risk of the infection.

show abstract

Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review

Iqbal

Soliman

Sanctis³

et al. 2021

Expert Review of Hematology

View full text Add to dashboard Cite

Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.

Cited by 4 publications

References 0 publications

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving ImatinibMesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

Risk and impact of tuberculosis in patients with chronic myeloid leukemia: A nationwide population‐based study in Taiwan

Association of tuberculosis in patients with chronic myeloid leukemia: a treatment proposal based on literature review

Contact Info

Product

Resources

About